MicroRNA-183-5p regulates TAR DNA-binding protein 43 neurotoxicity via SQSTM1/p62 in amyotrophic lateral sclerosis

Han-Cheon Kim1,2, Yan Zhang1,2, Peter H King3,4

  • 1Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

Journal of Neurochemistry
|December 17, 2022
PubMed

Insights

MicroRNA-183-5p is elevated in ALS, promoting toxic TDP-43 protein aggregation by suppressing SQSTM1/p62. Inhibiting this microRNA may offer a new therapeutic strategy for Amyotrophic Lateral Sclerosis (ALS).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron loss.
  • TDP-43 proteinopathy, including misfolding and aggregation, is a hallmark in over 95% of ALS cases.
  • MicroRNA (miRNA) dysregulation is implicated in neurotoxicity and mitochondrial dysfunction relevant to ALS.

Purpose of the Study:

  • To investigate the role of miR-183-5p in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS).
  • To elucidate the regulatory relationship between miR-183-5p, SQSTM1/p62, and TDP-43 protein in ALS.
  • To explore the therapeutic potential of modulating miR-183-5p in ALS models.

Main Methods:

  • Analysis of miR-183-5p expression in spinal cords of ALS patients.
  • Luciferase reporter assays to confirm miR-183-5p's regulation of SQSTM1/p62.
  • Experiments using miR-183-5p agomirs and antagomirs in cellular models to assess effects on SQSTM1/p62 and TDP-43 levels and aggregation.

Main Results:

  • miR-183-5p was found to be aberrantly upregulated in the spinal cords of ALS patients.
  • miR-183-5p directly suppresses SQSTM1/p62 expression.
  • Inhibition of miR-183-5p reduced TDP-43 aggregation and cytotoxicity, suggesting a protective role for SQSTM1/p62.

Conclusions:

  • The study identifies a novel mechanism of TDP-43 proteinopathy mediated by miR-183-5p.
  • A molecular link between aberrant RNA processing (miR-183-5p) and protein degradation (SQSTM1/p62) in ALS pathogenesis is established.
  • Modulating miR-183-5p activity presents a potential therapeutic avenue for ALS.